## **Core Concept**
The question presents a clinical scenario involving a 35-year-old male with bleeding, laboratory findings including leucocytosis, thrombocytopenia, and the presence of blasts and various immature cells in the peripheral smear, along with a specific chromosomal translocation t(8;21). This scenario suggests a diagnosis of acute leukemia, specifically a subtype characterized by the presence of this translocation.

## **Why the Correct Answer is Right**
The presence of the t(8;21) chromosomal translocation is highly suggestive of **Acute Myeloid Leukemia (AML) with RUNX1-RUNX1T1 fusion**, which is commonly associated with the M2 subtype of AML. This subtype is characterized by the maturation of myeloid cells (as evidenced by the presence of myelocytes, meta-myelocytes, and band forms) and the presence of blasts. The t(8;21) translocation leads to the fusion of the RUNX1 and RUNX1T1 genes, which plays a critical role in leukemogenesis. The clinical presentation of bleeding, leucocytosis, thrombocytopenia, and the specific findings on the peripheral smear support this diagnosis.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Without the specific details of Option A, it's not possible to directly refute it, but any option not associated with t(8;21) or not fitting the described laboratory and clinical picture would be incorrect.
- **Option B:** Similarly, without specifics, any diagnosis not aligning with the provided cytogenetic and morphological findings would not be correct.
- **Option C:** This option would be incorrect if it does not match the diagnosis associated with t(8;21) and the described myeloid lineage involvement.
- **Option D:** This would be incorrect if it suggests a different diagnosis not supported by the provided information, such as a lymphoid malignancy or another type of leukemia not associated with t(8;21).

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the **t(8;21) translocation is strongly associated with AML-M2 subtype** and generally confers a more favorable prognosis compared to other AML subtypes, especially when treated appropriately. This specific cytogenetic abnormality is a critical factor in the diagnosis and management planning of AML.

## **Correct Answer:** C. Acute Myeloid Leukemia (AML) M2 with t(8;21).